Sangamo Therapeutics (SGMO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SGMO Stock Forecast

Sangamo Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 385.83% upside from SGMO’s last price of $2.47) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

SGMO Price Target

The average price target for Sangamo Therapeutics (SGMO) is $12.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $5.00. This represents a potential 385.83% upside from SGMO's last price of $2.47.

SGMO Analyst Ratings

Buy

According to 4 Wall Street analysts, Sangamo Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SGMO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Sangamo Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 13, 2022	Andreas Argyrides	Wedbush	$5.00	$3.76	32.98%	102.43%
Apr 05, 2022	Nicole Germino	Truist Financial	$19.00	$6.15	208.94%	669.23%

The latest Sangamo Therapeutics stock forecast, released on Jun 13, 2022 by Andreas Argyrides from Wedbush, set a price target of $5.00, which represents a 32.98% increase from the stock price at the time of the forecast ($3.76), and a 102.43% increase from SGMO last price ($2.47).

Sangamo Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.47	$2.47	$2.47
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Sangamo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sangamo Therapeutics's last price of $2.47. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 23, 2024	Cowen & Co.	Buy	Buy	Hold
May 15, 2024	H.C. Wainwright	Underperform	Underperform	Hold
May 15, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Mar 13, 2024	H.C. Wainwright	Buy	Buy	Hold
Jan 19, 2024	Wells Fargo	Sector Perform	Sector Perform	Hold
Jan 19, 2024	RBC Capital	Underperform	Underperform	Hold
Nov 03, 2023	RBC Capital		Sector Perform	Downgrade
Feb 27, 2023	Wedbush		Outperform	Upgrade
Jan 04, 2023	Wells Fargo	Overweight	Overweight	Hold

Sangamo Therapeutics's last stock rating was published by Cowen & Co. on Oct 23, 2024. The company gave SGMO a "Buy" rating, the same as its previous rate.

Sangamo Therapeutics Financial Forecast

Sangamo Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$2.04M	$9.40M	$6.83M	$157.96M	$27.23M	$26.46M	$29.38M	$28.23M	$27.99M	$28.56M	$27.87M	$26.28M	$25.80M	$57.76M	$21.55M	$13.08M	$54.85M	$21.96M
Avg Forecast	$70.33M	$67.62M	$65.02M	$62.52M	$26.17M	$8.50M	$8.50M	$31.50M	$8.84M	$20.92M	$6.88M	$6.36M	$8.11M	$9.36M	$16.75M	$24.07M	$26.86M	$26.59M	$24.63M	$27.29M	$26.82M	$25.96M	$26.53M	$28.49M	$31.42M	$26.55M	$102.71M	$22.74M	$15.54M	$12.16M
High Forecast	$131.86M	$126.79M	$121.91M	$117.22M	$49.06M	$15.94M	$15.94M	$59.06M	$11.30M	$39.22M	$6.88M	$6.36M	$14.87M	$17.55M	$31.41M	$45.12M	$50.36M	$26.59M	$24.63M	$27.29M	$26.82M	$25.96M	$26.53M	$28.49M	$31.42M	$26.55M	$102.71M	$22.74M	$15.54M	$12.16M
Low Forecast	$39.16M	$37.65M	$36.20M	$34.81M	$14.57M	$4.73M	$4.73M	$17.54M	$6.38M	$11.65M	$6.88M	$6.36M	$3.08M	$5.21M	$9.33M	$13.40M	$14.95M	$26.59M	$24.63M	$27.29M	$26.82M	$25.96M	$26.53M	$28.49M	$31.42M	$26.55M	$102.71M	$22.74M	$15.54M	$12.16M
# Analysts	1	1	1	1	1	1	1	2	4	2	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.25%	1.00%	0.41%	6.56%	1.01%	1.00%	1.19%	1.03%	1.04%	1.10%	1.05%	0.92%	0.82%	2.18%	0.21%	0.58%	3.53%	1.81%

Sangamo Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $6.36M, with a low forecast of $6.36M, and a high forecast of $6.36M. SGMO's average Quarter revenue forecast represents a 211.32% increase compared to the company's last Quarter revenue of $2.04M (Dec 23).

Sangamo Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	4	2	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-59.38M	$-106.41M	$-123.57M	$140.76M	$-55.39M	$-54.89M	$-40.73M	$-40.32M	$-32.70M	$-43.01M	$-42.86M	$-41.77M	$-36.83M	$1.97M	$-32.70M	$-39.72M	$11.42M	$-26.15M
Avg Forecast	$-63.08M	$-60.65M	$-58.32M	$-56.08M	$-23.47M	$-7.62M	$-7.62M	$-28.25M	$-7.93M	$-18.76M	$-6.17M	$-49.85M	$-7.27M	$-8.40M	$-15.02M	$-45.32M	$-44.44M	$-24.05M	$-22.28M	$-41.20M	$-24.26M	$-23.48M	$-24.00M	$-37.45M	$-28.42M	$-24.02M	$-92.90M	$-28.76M	$-14.06M	$-11.00M
High Forecast	$-35.12M	$-33.77M	$-32.47M	$-31.22M	$-13.07M	$-4.25M	$-4.25M	$-15.73M	$-5.73M	$-10.45M	$-6.17M	$-39.88M	$-2.76M	$-4.67M	$-8.37M	$-36.25M	$-35.55M	$-24.05M	$-22.28M	$-32.96M	$-24.26M	$-23.48M	$-24.00M	$-29.96M	$-28.42M	$-24.02M	$-92.90M	$-23.01M	$-14.06M	$-11.00M
Low Forecast	$-118.27M	$-113.72M	$-109.35M	$-105.14M	$-44.01M	$-14.29M	$-14.29M	$-52.97M	$-10.14M	$-35.18M	$-6.17M	$-59.82M	$-13.34M	$-15.74M	$-28.17M	$-54.38M	$-53.33M	$-24.05M	$-22.28M	$-49.44M	$-24.26M	$-23.48M	$-24.00M	$-44.94M	$-28.42M	$-24.02M	$-92.90M	$-34.51M	$-14.06M	$-11.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	8.17%	12.67%	8.23%	-3.11%	1.25%	2.28%	1.83%	0.98%	1.35%	1.83%	1.79%	1.12%	1.30%	-0.08%	0.35%	1.38%	-0.81%	2.38%

3 analysts predict SGMO's average Quarter EBITDA for Jun 23 to be $-15.02M, with a high of $-8.37M and a low of $-28.17M. This is -110.67% lower than Sangamo Therapeutics's previous annual EBITDA (Mar 23) of $140.76M.

Sangamo Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	4	2	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-60.30M	$-104.16M	$-114.51M	$21.13M	$-51.97M	$-53.16M	$-43.17M	$-43.98M	$-37.50M	$-47.69M	$-47.17M	$-45.93M	$-40.60M	$-1.55M	$-35.93M	$-42.91M	$4.55M	$-27.31M
Avg Forecast	$-13.85M	$-15.15M	$-16.46M	$-17.77M	$-15.00M	$-21.43M	$-20.36M	$43.40M	$-16.34M	$-3.27M	$-31.45M	$-54.81M	$-54.94M	$-68.34M	$-72.09M	$-49.83M	$-50.95M	$-72.49M	$-71.94M	$-45.30M	$-70.45M	$-68.71M	$-63.85M	$-41.18M	$-43.39M	$-49.35M	$22.18M	$-31.07M	$-66.54M	$-69.60M
High Forecast	$-5.87M	$-6.42M	$-6.98M	$-7.53M	$-6.36M	$-9.08M	$-8.63M	$92.77M	$-8.17M	$-1.39M	$-13.33M	$-43.85M	$-39.56M	$-28.97M	$-30.56M	$-39.86M	$-40.76M	$-72.49M	$-71.94M	$-36.24M	$-70.45M	$-68.71M	$-63.85M	$-32.95M	$-43.39M	$-49.35M	$22.18M	$-24.86M	$-66.54M	$-69.60M
Low Forecast	$-29.59M	$-32.39M	$-35.18M	$-37.98M	$-32.07M	$-45.81M	$-43.52M	$18.40M	$-24.51M	$-6.99M	$-67.22M	$-65.77M	$-68.12M	$-146.08M	$-154.10M	$-59.80M	$-61.14M	$-72.49M	$-71.94M	$-54.36M	$-70.45M	$-68.71M	$-63.85M	$-49.42M	$-43.39M	$-49.35M	$22.18M	$-37.29M	$-66.54M	$-69.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.10%	1.52%	1.59%	-0.42%	1.02%	0.73%	0.60%	0.97%	0.53%	0.69%	0.74%	1.12%	0.94%	0.03%	-1.62%	1.38%	-0.07%	0.39%

Sangamo Therapeutics's average Quarter net income forecast for Jun 23 is $-72.09M, with a range of $-154.10M to $-30.56M. SGMO's average Quarter net income forecast represents a -441.14% decrease compared to the company's last Quarter net income of $21.13M (Mar 23).

Sangamo Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	4	2	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$10.22M	$13.92M	$16.01M	$18.14M	$16.44M	$16.24M	$15.09M	$14.91M	$16.08M	$14.50M	$16.49M	$16.15M	$16.87M	$16.18M	$17.93M	$16.12M	$15.05M	$14.92M
Avg Forecast	$37.29M	$35.86M	$34.48M	$33.15M	$13.88M	$4.51M	$4.51M	$16.70M	$4.69M	$11.09M	$3.65M	$3.37M	$4.30M	$4.96M	$8.88M	$17.52M	$21.86M	$13.39M	$12.41M	$15.93M	$13.51M	$13.08M	$13.37M	$14.48M	$15.83M	$13.38M	$51.75M	$11.67M	$7.83M	$6.13M
High Forecast	$69.92M	$67.23M	$64.65M	$62.16M	$26.02M	$8.45M	$8.45M	$31.32M	$5.99M	$20.80M	$3.65M	$3.37M	$7.89M	$9.31M	$16.65M	$21.02M	$26.23M	$13.39M	$12.41M	$19.11M	$13.51M	$13.08M	$13.37M	$17.37M	$15.83M	$13.38M	$51.75M	$14.01M	$7.83M	$6.13M
Low Forecast	$20.76M	$19.97M	$19.20M	$18.46M	$7.73M	$2.51M	$2.51M	$9.30M	$3.39M	$6.18M	$3.65M	$3.37M	$1.63M	$2.76M	$4.95M	$14.01M	$17.48M	$13.39M	$12.41M	$12.74M	$13.51M	$13.08M	$13.37M	$11.58M	$15.83M	$13.38M	$51.75M	$9.34M	$7.83M	$6.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	2.38%	2.80%	1.80%	1.04%	0.75%	1.21%	1.22%	0.94%	1.19%	1.11%	1.23%	1.12%	1.07%	1.21%	0.35%	1.38%	1.92%	2.43%

Sangamo Therapeutics's average Quarter SG&A projection for Mar 24 is $3.37M, based on 3 Wall Street analysts, with a range of $3.37M to $3.37M. The forecast indicates a -67.01% fall compared to SGMO last annual SG&A of $10.22M (Dec 23).

Sangamo Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	4	2	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.34	$-0.59	$-0.66	$0.13	$-0.32	$-0.34	$-0.29	$-0.30	$-0.26	$-0.33	$-0.33	$-0.32	$-0.29	$-0.01	$-0.26	$-0.37	$0.04	$-0.24
Avg Forecast	$-0.06	$-0.07	$-0.08	$-0.08	$-0.07	$-0.10	$-0.10	$0.20	$-0.08	$-0.02	$-0.15	$-0.21	$-0.26	$-0.32	$-0.34	$-0.33	$-0.36	$-0.36	$-0.35	$-0.31	$-0.35	$-0.34	$-0.31	$-0.29	$-0.21	$-0.24	$0.11	$-0.28	$-0.33	$-0.34
High Forecast	$-0.03	$-0.03	$-0.03	$-0.04	$-0.03	$-0.04	$-0.04	$0.43	$-0.04	$-0.01	$-0.06	$-0.09	$-0.18	$-0.14	$-0.14	$-0.14	$-0.15	$-0.36	$-0.35	$-0.31	$-0.35	$-0.34	$-0.31	$-0.29	$-0.21	$-0.24	$0.11	$-0.28	$-0.33	$-0.34
Low Forecast	$-0.14	$-0.15	$-0.16	$-0.18	$-0.15	$-0.21	$-0.20	$0.09	$-0.11	$-0.03	$-0.31	$-0.46	$-0.32	$-0.68	$-0.72	$-0.70	$-0.77	$-0.36	$-0.35	$-0.31	$-0.35	$-0.34	$-0.31	$-0.29	$-0.21	$-0.24	$0.11	$-0.28	$-0.33	$-0.34
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.33%	1.85%	1.96%	-0.40%	0.89%	0.96%	0.82%	0.96%	0.75%	0.98%	1.05%	1.09%	1.36%	0.04%	-2.39%	1.34%	-0.12%	0.70%

According to 3 Wall Street analysts, Sangamo Therapeutics's projected average Quarter EPS for Jun 23 is $-0.34, with a low estimate of $-0.72 and a high estimate of $-0.14. This represents a -358.75% decrease compared to SGMO previous annual EPS of $0.13 (Mar 23).

Sangamo Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EDIT	Editas Medicine	$1.52	$10.20	571.05%	Buy
SGMO	Sangamo Therapeutics	$2.82	$12.00	325.53%	Buy
NTLA	Intellia Therapeutics	$13.13	$53.00	303.66%	Buy
BLUE	bluebird bio	$8.97	$13.69	52.62%	Hold
ALNY	Alnylam Pharmaceuticals	$246.58	$310.60	25.96%	Buy

SGMO Forecast FAQ

Is Sangamo Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Sangamo Therapeutics (SGMO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of SGMO's total ratings.

What is SGMO's price target?

Sangamo Therapeutics (SGMO) average price target is $12 with a range of $5 to $19, implying a 385.83% from its last price of $2.47. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sangamo Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SGMO stock, the company can go up by 385.83% (from the last price of $2.47 to the average price target of $12), up by 669.23% based on the highest stock price target, and up by 102.43% based on the lowest stock price target.

Can Sangamo Therapeutics stock reach $4?

SGMO's average twelve months analyst stock price target of $12 supports the claim that Sangamo Therapeutics can reach $4 in the near future.

What are Sangamo Therapeutics's analysts' financial forecasts?

Sangamo Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $74.67M (high $140M, low $41.58M), average EBITDA is $-66.97M (high $-37.29M, low $-126M), average net income is $-13.395M (high $68.69M, low $-103M), average SG&A $39.59M (high $74.24M, low $22.05M), and average EPS is $-0.0625 (high $0.321, low $-0.481). SGMO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $265.49M (high $497.79M, low $147.83M), average EBITDA is $-238M (high $-133M, low $-446M), average net income is $-63.226M (high $-26.799M, low $-135M), average SG&A $140.78M (high $263.95M, low $78.39M), and average EPS is $-0.295 (high $-0.125, low $-0.631).

Did the SGMO's actual financial results beat the analysts' financial forecasts?

Based on Sangamo Therapeutics's last annual report (Dec 2023), the company's revenue was $176.23M, beating the average analysts forecast of $58.28M by 202.39%. Apple's EBITDA was $-274M, beating the average prediction of $-76.005M by 260.51%. The company's net income was $-258M, beating the average estimation of $-245M by 5.15%. Apple's SG&A was $61.17M, beating the average forecast of $35.66M by 71.53%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.24 by 19.38%. In terms of the last quarterly report (Dec 2023), Sangamo Therapeutics's revenue was $2.04M, missing the average analysts' forecast of $8.1M by -74.81%. The company's EBITDA was $-59.381M, beating the average prediction of $-7.27M by 716.85%. Sangamo Therapeutics's net income was $-60.296M, beating the average estimation of $-54.938M by 9.75%. The company's SG&A was $10.22M, beating the average forecast of $4.3M by 137.73%. Lastly, the company's EPS was $-0.34, beating the average prediction of $-0.256 by 32.64%